| UHC Surest Medical and Drug | Saphnelo® (Anifrolumab-Fnia) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-07-01 |
| UHC Surest Medical and Drug | Scenesse® (Afamelanotide) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-07-01 |
| UHC Surest Medical and Drug | Tocilizumab Injection for Intravenous Infusion – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC UMR Medical and Drug | Adzynma (ADAMTS13, Recombinant-Krhn) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-07-01 |
| UHC UMR Medical and Drug | Korsuva® (Difelikefalin) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-07-01 |
| UHC UMR Medical and Drug | Saphnelo® (Anifrolumab-Fnia) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-07-01 |
| UHC UMR Medical and Drug | Scenesse® (Afamelanotide) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-07-01 |
| UHC UMR Medical and Drug | Tocilizumab Injection for Intravenous Infusion – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Adzynma (ADAMTS13, Recombinant-Krhn) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-07-01 |
| UHC Commercial Medical & Drug | Korsuva® (Difelikefalin) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-07-01 |